<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2128">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05133453</url>
  </required_header>
  <id_info>
    <org_study_id>Pirfenidone in asbestosis</org_study_id>
    <nct_id>NCT05133453</nct_id>
  </id_info>
  <brief_title>Pirfenidone Use in Asbestosis Patients: Efficacy and Prognosis</brief_title>
  <official_title>Pirfenidone Use in Asbestosis Patients: Efficacy and Prognosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at determining the the efficiency and prognosis of using pirfenidone drug&#xD;
      among asbestosis patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asbestos exposure is associated with pleural and lung fibrosis and lung cancer. It has&#xD;
      pathomechanisms and clinical similarities to interstitial pulmonary fibrosis disease. There&#xD;
      is no definite cure for asbestosis. Pirfenidone has antifibrotic and anti-inflammatory&#xD;
      effects.The safety and effectiveness of pirfenidone for the treatment of non-interstitial&#xD;
      pulmonary fibrosis progressive fibrotic interstitial lung diseases remain unclear including&#xD;
      asbestosis. Only few studies for pirfenidone use in asbestosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilatory function change</measure>
    <time_frame>after 6 months and 12 months from the start of the trial</time_frame>
    <description>Absolute change in percent predicted forced vital capacity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diffusion test</measure>
    <time_frame>after 6 months and 12 months from the start of the trial</time_frame>
    <description>Diffusion test change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>radiological findings change</measure>
    <time_frame>after 6 months and 12 months from the start of the trial</time_frame>
    <description>radiological changes in High resolution computed topography.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Asbestosis</condition>
  <arm_group>
    <arm_group_label>Pirfinedone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>asbestosis patients given pirfenidone drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Asbestosis patients on conventional treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>drug intake three times daily for one year</description>
    <arm_group_label>Pirfinedone group</arm_group_label>
    <other_name>Conventional treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male patients aged ≥ 18 years old&#xD;
&#xD;
          -  Patients who fulfilled investigations according the study protocol.&#xD;
&#xD;
          -  Patients who kept on follow up for the entire study.&#xD;
&#xD;
          -  All patients fulfilling the clinical and radiological criteria of asbestosis&#xD;
             (Existence of asbestos-specific pleural changes in high resolution computed topography&#xD;
             HRCT (pleural plaques), Reticular changes in HRCT and restrictive lung function&#xD;
             pattern, History of asbestos exposure, Absence of an alternative explanation for&#xD;
             fibrotic lung disease )&#xD;
&#xD;
          -  Clinically stable patients.&#xD;
&#xD;
          -  Patients who signed informed consent&#xD;
&#xD;
          -  Patients with mild-to-moderate IPF [forced vita capacity (FVC) ≥50% of predicted and&#xD;
             diffusion capacity of carbon monoxide (DLCO) ≥30% of predicted].&#xD;
&#xD;
          -  Duration since diagnosis (at least one year before the study)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with peptic ulcer,&#xD;
&#xD;
          -  Severe hepatic disease, hepatitis C infection or any of the following liver function&#xD;
             test criteria above specified limits: aspartate or alanine aminotransferase (AST or&#xD;
             ALT) &gt;2.5 u above upper limit of normal level.&#xD;
&#xD;
          -  Severe kidney disease, Cardiac disease, and Patients with other chronic pulmonary&#xD;
             diseases, lung cancer&#xD;
&#xD;
          -  Presence of coexisting respiratory infection&#xD;
&#xD;
          -  History of alcohol or drugs abuse&#xD;
&#xD;
          -  Patients with neuromuscular disease,&#xD;
&#xD;
          -  Chronic renal failure,&#xD;
&#xD;
          -  Patient on oxygen therapy,&#xD;
&#xD;
          -  Life expectancy less than 6 months,&#xD;
&#xD;
          -  History of malignancy.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marwa M Fouad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marwa M Fouad, MD</last_name>
    <phone>01004531905</phone>
    <email>marwa.fouad@kasralainy.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohammed Elbatanouny, MD</last_name>
    <phone>01222174324</phone>
    <email>elbatanounym@yahoo.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, Bonnet R, Grohe C, Held M, Wilkens H, Hammerl P, Koschel D, Blaas S, Wirtz H, Ficker JH, Neumeister W, Schönfeld N, Claussen M, Kneidinger N, Frankenberger M, Hummler S, Kahn N, Tello S, Freise J, Welte T, Neuser P, Günther A; RELIEF investigators. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021 May;9(5):476-486. doi: 10.1016/S2213-2600(20)30554-3. Epub 2021 Mar 30.</citation>
    <PMID>33798455</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Marwa Mohammed Fouad</investigator_full_name>
    <investigator_title>Lecturer of Occupational and environmental Medicine</investigator_title>
  </responsible_party>
  <keyword>Pirfenidone</keyword>
  <keyword>Asbestosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asbestosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

